

**A reply letter to 'Efficacy and Safety of Nemolizumab for Treatment of Adult Atopic Dermatitis'**

Lihang L<sup>1</sup>, Han Y<sup>1</sup>

<sup>1</sup>Department of Dermatology, the Union Hospital, Fujian Medical University, Fuzhou, P.R. China

**Corresponding author**

Yue Han, M.D., Ph.D.

Xinquan Road 29,

Fuzhou 350001, P.R. China.

Email: dr\_hanyue@126.com

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.18176/jiaci.0745

**Key Words:** Nemolizumab. Atopic Dermatitis.

**Palabras clave:** Nemolizumab. Dermatitis atópica.

To the Editor:

Firstly, we would like to thank Freemantle et al [1] for a kind letter and their constructive comments concerning our article 'Efficacy and Safety of Nemolizumab for Treatment of Adult Atopic Dermatitis' [2] which are very valuable and helpful, as well as the important guiding significance to our researches. We have studied comments carefully, seriously discussed and have made explanation which we hope address the troubling. The main explanation about the paper and the responds to readers' comments are as following:

After our meta-analysis, we made a conclusion that 60mg Q4w is likely to be optimal for the treatment of patients with moderate-to-severe atopic dermatitis. However, the evaluation of the optimal therapeutic method should consider both the drug efficacy and drug safety. So the way of analyzing data is not only based on EASI score of the studies but the AE and SAE results as well. As shown in Supplementary Figure 4, we found that the rate AE of 60mg Q4w is lower than that of 30mg Q4w (RR(95%CI):1.00(0.83,1.20) vs 1.07(0.89,1.30)); compared with the 60mg Q4w group, the rate of SAE of 30mg Q4w group is significantly higher (RR(95%CI):0.76(0.13,4.42)

vs 1.13(0.70,1.81))<sup>[1]</sup>. Moreover, the cause of heterogeneity indicated by Galbraith radial plot should be also considered in our evaluation. As shown in Supplementary Figure 3, 60mg Q4w group is closer to the middle line compared with 30mg Q4w group, indicating that the heterogeneity of effect in 60mg Q4w group is less than 30mg Q4w group<sup>[1]</sup>.

With above combination, we reached a little different conclusion. Anyhow, we all feel really sorry for our previous unclear explanations in detail because of the word limit. Meanwhile, in the future, with the increase of phase III clinical trials, the current results will be updated and conclusions may change. Finally, thanks again for our reader friends' positive comments and valuable suggestions to improve the quality of our article.

Yours Sincerely.

### **Funding sources**

Fujian Provincial Health Technology Project (2020GGA030) and Fujian Talent Introduction Project (2020XH003).

### **Conflicts of Interest**

None declared.

## References

1. Freemantle N, Piketty C. Efficacy and Safety of Nemolizumab for Treatment of Adult Atopic Dermatitis. *J Investig Allergol Clin Immunol* 2021;Vol31(6): In press. doi: 10.18176/jiaci.0727
2. Xuemin X, Lihang L, Changhua Z, Xiaofang Y, Yongshan N, Zhipeng L, et al. Efficacy and safety of nemolizumab for adult atopic dermatitis treatment: A meta-analysis of randomized clinical trials. *J Investig Allergol Clin Immunol*. 2021;31(2):190-2.